Special Directions For Use In Tetanus

There is clinical evidence which suggests that methocarbamol may have a beneficial effect in the control of the neuromuscular manifestations of tetanus. It does not, however, replace the usual procedure of debridement, tetanus antitoxin, penicillin, tracheotomy, attention to fluid balance, and supportive care. ROBAXIN Injectable should be added to the regimen as soon as possible.

For Adults

Inject one or two vials directly into the tubing of the previously inserted indwelling needle. An additional 10 mL or 20 mL may be added to the infusion bottle so that a total of up to 30 mL (three vials) is given as the initial dose (see PRECAUTIONS). This procedure should be repeated every six hours until conditions allow for the insertion of a nasogastric tube. Crushed methocarbamol tablets suspended in water or saline may then be given through this tube. Total daily oral doses up to 24 grams may be required as judged by patient response.

For Pediatric Patients

A minimum initial dose of 15 mg/kg or 500 mg/m² is recommended. This dosage may be repeated every six hours, if required. The total dose should not exceed 1.8 g/m² for 3 consecutive days. The maintenance dosage may be given by injection into tubing or by I.V. infusion with  an appropriate quantity of fluid. See directions for I.V. use.


ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6103-25).

Store at 20°- 25°C (68°- 77°F), excurs ions permitted to 15°- 30°C (59°- 86°F).

Not made with natural rubber latex.

To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1- 877-845-0689 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For Product Inquiry call 1-877-845-0689.

Manufactured by: WEST-WARD A HIKMA COMPANY, Eatontown, NJ 07724 USA. Revised: Oct 2017